News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
HENGRUI PHARMA's SHR-3079 Injection Approved for Clinical Trials
HENGRUI PHARMA (01276.HK) announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received the Drug Clinical Trial Approval Notice for the SHR-3079 injection issued ...
Reset
Send
The window will close in 5 seconds
HENGRUI PHARMA's SHR-3079 Injection Approved for Clinical Trials
Close
Recommend
4
Positive
5
Negative
1
 
 

HENGRUI PHARMA (01276.HK)  0.000 (0.000%)    Short selling $46.38M; Ratio 20.840%   announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received the Drug Clinical Trial Approval Notice for the SHR-3079 injection issued by the National Medical Products Administration, and will commence clinical trials in the near term.

SHR-3079 injection is an innovative anti-tumor drug independently developed by the company, and is intended for the treatment of B-cell non-Hodgkin lymphoma.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-19 16:25.)

Related News Citi Cuts HSI 2026 TP to 29,600; TENCENT (00700.HK), AIA (01299.HK) Among Top H Shrs Picks

Auto-translated by AI
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.